Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3190840 | 1.00 | PTGS2 (0.53) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL3190836 | 1.00 | PTGS2 (0.53) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL2909491 | 1.00 | PTGS2 (0.53) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL4787112 | 0.88 | S100B (0.56) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL4787108 | 0.88 | S100B (0.56) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL20186948 | 0.84 | PTGS2 (0.67) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL12416601 | 0.84 | PTGS2 (0.67) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL2455348 | 0.84 | PTGS2 (0.67) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL2455350 | 0.84 | PTGS2 (0.67) | PTGS2CA1CA2CA9PTGS1 | |
| SCHEMBL12416606 | 0.84 | PTGS2 (0.67) | PTGS2CA1CA2CA9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160282-A1 | NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-24 | — | — | US | disclosed |
| US-7674773-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7671047-B2 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-7579339-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-7407938-B2 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-08-05 | — | — | US | disclosed |
| US-7390790-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-24 | — | — | US | disclosed |
| US-7388004-B2 | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-06-17 | — | — | US | disclosed |
| US-20070123506-A1 | Acid-group-substituted diphenylazetidinones process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2007-05-31 | — | — | US | disclosed |
| US-20070043017-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2007-02-22 | — | — | US | disclosed |
| US-20070037787-A1 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2007-02-15 | — | — | US | disclosed |
| US-7176194-B2 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20060270613-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2006-11-30 | — | — | US | disclosed |
| US-6992067-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-01-31 | — | — | US | disclosed |
| US-20050267038-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-12-01 | — | — | US | disclosed |
| US-20040082561-A1 | Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20040077623-A1 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040067913-A1 | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-04-08 | — | — | US | disclosed |
| US-6498156-B2 | TREATING HYPERLIPIDEMIA, ARTERIOSCLEROSIS AND HYPERCHOLESTEROLEMIA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-24 | — | — | US | disclosed |
| US-20020137689-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-26 | — | — | US | disclosed |
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043017-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | PTGS2 982/4885CA1 4601/4885CA2 3214/4885 |
| US-20020137689-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB7, NDUFB6 | PTGS2 1532/4885CA1 4868/4885CA2 4405/4885 |
| US-20040082561-A1 | Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | PTGS2 884/4885CA1 4524/4885CA2 3141/4885 |
| US-20060270613-A1 | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, CYP2D6, DHCR7 | PTGS2 982/4885CA1 4601/4885CA2 3214/4885 |
| US-20040067913-A1 | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | CYP2D6, QDPR, CYP26A1 | PTGS2 1099/4885CA1 3225/4885CA2 1578/4885 |
| US-20050267038-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | PTGS2 1626/4885CA1 4873/4885CA2 4428/4885 |
| US-20070037787-A1 | 1,4-Diphenyl-3-(3-hydroxy-3-phenylpropyl)-2-azetidinones, e.g., 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-y]lbenzylcarbamoyl}phenoxy)benzoic acid; antilipemic agents that have intestinal absorption of less than 10%, | HPD, FABP2, CYP2B6 | PTGS2 660/4885CA1 3960/4885CA2 1755/4885 |
| US-20040077623-A1 | Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use | QDPR, DRD4, CYP2D6 | PTGS2 1935/4885CA1 4374/4885CA2 2139/4885 |
| US-20070123506-A1 | Acid-group-substituted diphenylazetidinones process for their preparation, medicaments comprising these compounds, and their use | CYP2D6, QDPR, CYP2A6 | PTGS2 916/4885CA1 3798/4885CA2 1980/4885 |
| US-20100160282-A1 | NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE | QDPR, NDUFB6, NDUFB7 | PTGS2 1626/4885CA1 4873/4885CA2 4428/4885 |
| US-20020128252-A1 | Diphenylazetidinone derivatives, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | PTGS2 1665/4885CA1 4848/4885CA2 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.